Huskisson E C, Scott D L
Department of Rheumatology, St Bartholomews Hospital, London.
Eur J Rheumatol Inflamm. 1991;11(2):4-7.
One hundred patients with rheumatoid arthritis were entered into a randomised, double-blind, cross-over study of naproxen (500 mg b.d.) and diclofenac (50 mg t.i.d.). Each treatment period lasted four weeks with a wash-out period of up to one week on admission and again between periods of active therapy. Compared with baseline, both treatments significantly reduced the duration of morning stiffness, Ritchie Articular Index, daytime and night-time pain and produced a significant improvement in the disease status. Forty-two non-serious presumed side-effects were reported in 21 patients (21%). All were characterised by common everyday signs and symptoms. These largely related to the upper gastrointestinal tract and typical of those commonly reported for non-steroidal anti-inflammatory agents. There were no statistically significant differences between the two treatments for any of the efficacy parameters or in the incidence of side-effects. Patients also expressed an equal preference for the two drugs.
100名类风湿性关节炎患者参与了一项关于萘普生（每日两次，每次500毫克）和双氯芬酸（每日三次，每次50毫克）的随机、双盲、交叉研究。每个治疗期持续四周，入院时及积极治疗期之间有长达一周的洗脱期。与基线相比，两种治疗均显著缩短了晨僵持续时间、降低了里奇关节指数、减轻了白天和夜间疼痛，并使疾病状态有显著改善。21名患者（21%）报告了42例非严重的疑似副作用。所有这些都表现为常见的日常体征和症状。这些主要与上消化道有关，是非甾体抗炎药常见报告的典型症状。两种治疗在任何疗效参数或副作用发生率方面均无统计学显著差异。患者对这两种药物的偏好也相同。
